Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechanism of action and the latest preclinical data demonstrating rapid, robust, and selective target removal Biohaven announces it will present safety and IgG lowering data from its ongoing single ascending dose (SAD) study of BHV-1300 at the company's annual R&D day at the Yale Innovation Summit in New Haven, Connec ...

Exhibit 99.1 Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments • Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: ◦ Portfolio targeting large indications including obesity, epilepsy, bipolar disorder, depression, obsessivecompulsive disorder (OCD), migraine, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and cancer. Also ad ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________________________________________________ FORM 10-K ____________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to __ ...

Part I [Part I: Financial Information](index=1&type=section&id=Part%20I%20Financial%20Information) [Item 1: Condensed Consolidated Financial Statements (Unaudited)](index=1&type=section&id=Item%201%3A%20Condensed%20Consolidated%20Financial%20Statements%20%28Unaudited%29) Biohaven's unaudited financial statements for the period ended September 30, 2023, detail a **net loss of $263.4 million** and **total assets of $382.7 million** [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to **$382.7 million** as of September 30, 2023, primarily due to reduced cash and marketable securities Condensed Consolidated Balance Sheet Data (in thousands) | Account | Sep 30, 2023 (Unaudited) | Dec 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $111,697 | $204,877 | | Marketable securities | $128,899 | $260,464 | | Total current assets | $310,570 | $586,968 | | Total assets | $382,736 | $661,783 | | **Liabilities & Equity** | | | | Total current liabilities | $62,177 | $90,021 | | Total liabilities | $92,730 | $123,012 | | Total shareholders' equity | $290,006 | $538,771 | | Total liabilities and shareholders' equity | $382,736 | $661,783 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss decreased to **$263.4 million** for the nine months ended September 30, 2023, driven by lower R&D and G&A expenses Statement of Operations Highlights (in thousands, except per share data) | Metric | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | | Research and development | $238,468 | $300,028 | | General and administrative | $43,872 | $54,492 | | Total operating expenses | $282,340 | $354,520 | | Loss from operations | ($282,340) | ($354,520) | | Net loss | ($263,412) | ($369,172) | | Net loss per share — basic and diluted | ($3.86) | ($9.38) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was **$216.8 million** for the nine months ended September 30, 2023, with a net decrease in cash of **$116.6 million** Cash Flow Summary (in thousands) | Activity | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | ($216,844) | ($222,282) | | Net cash provided by (used in) investing activities | $133,744 | ($40,774) | | Net cash (used in) provided by financing activities | ($33,327) | $237,417 | | Net decrease in cash, cash equivalents, and restricted cash | ($116,614) | ($25,639) | | Cash, cash equivalents, and restricted cash at end of period | $125,990 | $51,418 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the spin-off, accounting policies, acquisitions, equity changes, and numerous license agreements with potential future milestone payments - The company became an independent, publicly traded entity on October 3, 2022, following a spin-off from its Former Parent, which was acquired by Pfizer[79](index=79&type=chunk)[80](index=80&type=chunk)[101](index=101&type=chunk) - In April 2022, the company acquired the Kv7 channel targeting platform from Knopp Biosciences for an upfront payment of **$35.0 million** in cash and approximately **$58.7 million** in common shares, with potential future milestone payments[157](index=157&type=chunk)[177](index=177&type=chunk) - The company has numerous license agreements with potential future milestone payments totaling approximately **$1.94 billion** across developmental (**$123.8 million**), regulatory (**$547.4 million**), and commercial (**$1.27 billion**) stages[188](index=188&type=chunk) - In March 2023, Biohaven entered into an exclusive license agreement with Hangzhou Highlightll for a brain-penetrant dual TYK2/JAK1 inhibitor program, with upfront consideration of **$10.0 million** in cash and **$10.0 million** in common shares, pending post-closing activities[24](index=24&type=chunk)[250](index=250&type=chunk) [Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202%3A%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial results, pipeline progress, and liquidity, highlighting decreased expenses and the upcoming change in filer status [Overview and Pipeline](index=29&type=section&id=Overview%20and%20Pipeline) Biohaven is advancing a diverse pipeline in neuroscience and rare diseases, with three programs currently in Phase 3 clinical trials - The company is advancing a broad pipeline with key platforms in Kv7 channel modulation, glutamate modulation, myostatin inhibition, and TYK2/JAK1 inhibition[61](index=61&type=chunk)[299](index=299&type=chunk) Key Clinical-Stage Milestones | Drug Name / Platform | Indication(s) | 2H 2023 Milestone | 2024 Milestone | | :--- | :--- | :--- | :--- | | **BHV-7000** (Kv7) | Focal Epilepsy | Initiate Phase 3 | - | | | Bipolar disorder | - | Initiate Phase 3 | | **BHV-7010** (Kv7) | Epilepsy & mood disorders | - | Submit IND | | **BHV-8000** (TYK2/JAK1) | Neuroinflammatory Disorders | - | Initiate Phase 2/3 (Parkinson's) | | **Troriluzole** | OCD | - | Complete Enrollment | | **Taldefgrobep Alfa** | SMA | Completed Enrollment | - | - An NDA for troriluzole in Spinocerebellar Ataxia Type 3 (SCA3) was submitted to the FDA but was not accepted for review; a Marketing Authorization Application (MAA) is currently under review by the EMA[285](index=285&type=chunk) - Enrollment was completed in September 2023 for the Phase 3 trial of taldefgrobep alfa in Spinal Muscular Atrophy (SMA)[307](index=307&type=chunk) [Results of Operations](index=42&type=section&id=Results%20of%20Operations) Operating expenses decreased for the nine months ended September 30, 2023, primarily due to lower R&D and G&A costs Comparison of Nine Months Ended Sep 30, 2023 and 2022 (in thousands) | Item | 2023 | 2022 | Change | | :--- | :--- | :--- | :--- | | Research and development | $238,468 | $300,028 | ($61,560) | | General and administrative | $43,872 | $54,492 | ($10,620) | | Loss from operations | ($282,340) | ($354,520) | $72,180 | | Net loss | ($263,412) | ($369,172) | $105,760 | - The decrease in R&D expenses for the nine-month period was primarily due to a one-time **$93.7 million** expense for the Kv7 Platform Acquisition and a **$25.0 million** milestone payment in 2022, which did not recur in 2023[363](index=363&type=chunk) - The income tax provision decreased significantly, resulting in a benefit for 2023, due to new IRS guidance on R&D expenditure deductions[283](index=283&type=chunk)[366](index=366&type=chunk) [Liquidity and Capital Resources](index=47&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains strong liquidity with **$111.7 million** in cash and expects current capital to fund operations for over one year - As of September 30, 2023, the company had cash and cash equivalents of **$111.7 million** and marketable securities of **$128.9 million**[392](index=392&type=chunk) - In October 2023, the company closed a public offering of common shares, raising net proceeds of approximately **$242.4 million** for general corporate purposes[1](index=1&type=chunk)[183](index=183&type=chunk) - The company also entered an 'at-the-market' equity distribution agreement in October 2023, allowing for the sale of up to **$150.0 million** in common shares[184](index=184&type=chunk)[404](index=404&type=chunk) - Management expects existing cash, cash equivalents, and marketable securities to be sufficient to fund operating expenses and other cash requirements for more than one year[2](index=2&type=chunk)[105](index=105&type=chunk) - The company will lose its 'emerging growth company' and 'smaller reporting company' status effective December 31, 2023, which will increase compliance costs and disclosure requirements[410](index=410&type=chunk)[435](index=435&type=chunk) [Item 3: Quantitative and Qualitative Disclosures About Market Risk](index=50&type=section&id=Item%203%3A%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's market risk exposure, including foreign currency, interest rate, and credit risk, is assessed as immaterial or well-managed - The company's exposure to foreign currency translation risk is currently immaterial[426](index=426&type=chunk)[440](index=440&type=chunk) - Interest rate risk is present in the investment portfolio; a hypothetical **1.00%** change in interest rates would impact the fair value by approximately **$0.2 million**[450](index=450&type=chunk) - Credit risk is managed by investing excess cash in highly-rated institutions and investment-grade securities, with policies to ensure diversification[428](index=428&type=chunk)[443](index=443&type=chunk) [Item 4: Controls and Procedures](index=50&type=section&id=Item%204%3A%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2023, with no material changes to internal controls - Based on an evaluation as of September 30, 2023, the CEO and CFO concluded that the company's disclosure controls and procedures were effective at the reasonable assurance level[431](index=431&type=chunk) - There were no material changes to the company's internal control over financial reporting during the three months ended September 30, 2023[432](index=432&type=chunk) Part II [Part II: Other Information](index=52&type=section&id=Part%20II%20Other%20Information) [Item 1: Legal Proceedings](index=52&type=section&id=Item%201%3A%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings and is unaware of any adverse pending actions - As of the report date, the company is not a party to any material legal proceedings and is not aware of any pending or threatened legal proceedings that could have a material adverse effect on its business[434](index=434&type=chunk) [Item 1A: Risk Factors](index=52&type=section&id=Item%201A%3A%20Risk%20Factors) No material changes to risk factors, except for increased compliance costs due to the upcoming change in filer status - The company's risk factors have not materially changed from its 2022 Form 10-K, except for a new risk related to its change in filer status[435](index=435&type=chunk) - Effective December 31, 2023, the company will become a 'large accelerated filer' and lose its 'emerging growth company' status, leading to increased compliance costs and regulatory requirements[410](index=410&type=chunk)[447](index=447&type=chunk) [Item 2: Unregistered Sales of Equity Securities and Use of Proceeds](index=52&type=section&id=Item%202%3A%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities, use of proceeds, or issuer purchases were reported during this period - None[412](index=412&type=chunk) [Item 6: Exhibits](index=53&type=section&id=Item%206%3A%20Exhibits) Exhibits filed with this report include CEO and CFO certifications and iXBRL data files for financial statements - The exhibits filed with this report include CEO and CFO certifications under the Sarbanes-Oxley Act and iXBRL formatted financial data[415](index=415&type=chunk)

Form 10-Q Table of Contents Preclinical and clinical data have demonstrated the potential for anti-myostatin therapies to produce physical and metabolic changes that are highly relevant to individuals living with overweight and obesity, including reducing total body fat and visceral adiposity, and improving insulin sensitivity and bone mineral density, while increasing lean muscle mass. In the fourth quarter of 2021, we initiated a Phase 1a/1b trial in multiple myeloma patients using its antibody recruiting ...

Financial Performance - Net loss for the three months ended March 31, 2023, was $70,492 thousand, a decrease from a net loss of $97,032 thousand in the same period of 2022, representing a 27.3% improvement[44] - The company reported net cash used in operating activities of $77,638 thousand for the three months ended March 31, 2023, compared to $58,836 thousand for the same period in 2022[44] - The company recorded total operating expenses of $77.8 million for the three months ended March 31, 2023, a decrease of $11.99 million from $89.77 million in the same period of 2022[80] - The net loss for the three months ended March 31, 2023, was $70.49 million, an improvement of $26.54 million compared to a net loss of $97.03 million in the same period of 2022[80] - The income tax provision decreased to $0.9 million for the three months ended March 31, 2023, from $7.3 million in the same period of 2022, primarily due to R&D tax credits[82] - The company anticipates continued significant general and administrative expenses as it supports R&D activities and prepares for potential commercialization of product candidates[77] - The company has incurred significant operating losses and negative cash flows from operations, with no revenue from product sales until successful completion of clinical development[100] Cash Flow and Financing - Cash used in operating activities for the three months ended March 31, 2023, was $77,638 thousand, compared to $58,836 thousand in the same period of 2022, indicating an increase of 32%[44] - Cash, cash equivalents, and restricted cash at the end of the period were $190,590 thousand, down from $242,604 thousand at the beginning of the period, reflecting a decrease of 21.5%[44] - The company’s cash flows from financing activities included a net cash provided of $26,668 thousand for the three months ended March 31, 2023, compared to $23,030 thousand in the same period of 2022, showing an increase of 15.5%[44] - Net cash provided by financing activities was $26.7 million for Q1 2023, an increase of $3.6 million compared to $23.0 million in Q1 2022, driven by the advancement of discovery programs and clinical-stage assets[103] - The company expects to require additional capital for in-licenses or acquisitions of other product candidates, especially if regulatory approval is obtained for its product candidates[104] Research and Development - The company is advancing a pipeline of therapies targeting neurological and neuropsychiatric diseases, including Kv7 ion channel modulation and TYK2/JAK1 inhibition[46] - BHV-7000 has received Rare Pediatric Disease Designation from the FDA for the treatment of KCNQ2 developmental epileptic encephalopathy[56] - The company is exploring new product candidates, including therapies for neuropathic pain and autoimmune brain disorders, leveraging its proprietary platforms[46][59] - The company plans to enroll approximately 180 patients in a Phase 3 trial evaluating taldefgrobep as an adjunctive therapy for SMA[66] - The company initiated a Phase 1a/1b trial in multiple myeloma patients, planning to enroll 30 patients to assess safety and tolerability of BHV-1100[67] - The company expects to submit an IND application for BHV-1300 with the FDA in the second half of 2023, following a preclinical study showing a 75% reduction of IgG levels[74] Operating Expenses - R&D expenses for Q1 2023 were $63.5 million, a decrease of $6.6 million from $70.1 million in Q1 2022, primarily due to reduced personnel-related costs[98] - General and administrative expenses for Q1 2023 were $14.3 million, down from $19.7 million in Q1 2022, mainly due to decreased non-cash share-based compensation costs[99] - The total operating expenses for Q1 2023 were $77.8 million, a decrease of $12.0 million compared to $89.8 million in Q1 2022[80] Risks and Challenges - The company is subject to risks typical of early-stage biotechnology firms, including competition and the need for significant additional capital for product development[28] - The company has not generated any revenue since inception and expects to incur significant expenses for several years as it advances product candidates through clinical development and seeks regulatory approval[100] - The company is subject to risks common to early-stage biotechnology companies, including dependence on key personnel and the need for significant additional capital for product development[28] Internal Controls and Compliance - There have been no material changes to the company's internal control over financial reporting during the three months ended March 31, 2023[93] - The company maintains a portion of its cash deposits in government insured institutions in excess of government insured limits, believing these institutions have high credit quality[91] - The company is subject to taxation in the BVI, where it benefits from exemptions from the Income Tax Ordinance for non-residents[96] - The company does not engage in any hedging activities against changes in interest rates[108] - As of March 31, 2023, the company's disclosure controls and procedures were effective at the reasonable assurance level[110] - Management acknowledges that disclosure controls can only provide reasonable, not absolute, assurance of meeting objectives[110] - The evaluation of disclosure controls involved a cost-benefit analysis of possible procedures[110] - There are inherent limitations in the control system, which may lead to undetected misstatements due to error or fraud[110] - The design of controls is based on assumptions about the likelihood of future events, which may change over time[110] - The Chief Executive Officer and Chief Financial Officer conducted an evaluation of the disclosure controls as of March 31, 2023[110] - Controls may become inadequate due to changes in conditions or compliance levels over time[110] - The company recognizes that the effectiveness of controls may deteriorate under certain future conditions[110] - Management's judgment was applied in evaluating the design of disclosure controls[110] - There is no assurance that any design will succeed in achieving its stated goals under all potential future conditions[110]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________________________________________________ FORM 10-K ____________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to __ ...

Financial Performance - For the three months ended September 30, 2022, total operating expenses were $67,637,000, an increase of 21.8% from $55,492,000 in the same period of 2021[9]. - The net loss attributable to common shareholders for the three months ended September 30, 2022, was $68,853,000, compared to a net loss of $54,365,000 for the same period in 2021, representing a 26.6% increase[9]. - The net loss per share attributable to common shareholders for the three months ended September 30, 2022, was $(1.75), compared to $(1.38) for the same period in 2021[9]. - For the nine months ended September 30, 2022, total operating expenses were $354.5 million, an increase of $186.5 million from $168.0 million in the same period of 2021[176]. - The company recorded a net loss of $68.9 million for the three months ended September 30, 2022, compared to a net loss of $54.4 million for the same period in 2021, an increase of $14.5 million[170]. - The provision for income taxes for the nine months ended September 30, 2022, was $14,581,000, compared to a benefit of $(1,091,000) in the same period of 2021[9]. Research and Development Expenses - Research and development expenses for the nine months ended September 30, 2022, were $300,028,000, compared to $139,668,000 for the same period in 2021, reflecting a 114.4% increase[9]. - Research and development expenses for the three months ended September 30, 2022, were $52.8 million, up from $47.0 million in the same period of 2021, reflecting an increase of $5.9 million[172]. - The Company recorded $25,000 thousand to R&D expense during the nine months ended September 30, 2022, for a regulatory milestone payment due to Knopp[52]. - Research and development expenses for the three months ended September 30, 2022, were $23,048,000, up from $17,396,000 in 2021, reflecting a year-over-year increase of 32.1%[97]. - Research and development expenses for the three months ended September 30, 2022, were $9,722, down from $10,187 in 2021, indicating a decrease of 4.6%[61]. Cash and Financing Activities - Cash and restricted cash at the end of the period on September 30, 2022, was $51,418,000, down from $362,690,000 at the end of the same period in 2021[14]. - As of October 3, 2022, the Company had a cash balance of approximately $257,799 following a cash contribution from the Former Parent[32]. - The Company completed a public offering on October 25, 2022, resulting in net proceeds of approximately $282,763[32]. - Net cash used in operating activities for the nine months ended September 30, 2022, was $222,282,000, compared to $112,784,000 for the same period in 2021, showing an increase of 97%[14]. - The company completed a public offering of 28,750,000 common shares at a price of $10.50 per share, raising approximately $282.8 million in net proceeds[184]. Company Structure and Spin-Off - Biohaven Ltd. became an independent, publicly traded company following the spin-off from its former parent on October 3, 2022, with 35,832,557 common shares issued[19]. - Following the Spin-Off on October 3, 2022, the Company issued an aggregate of 35,832,557 common shares to holders of Former Parent common shares[119]. - The Transition Services Agreement with the Former Parent includes provisions for finance, IT, clinical study support, and other services to ensure an orderly transition post Spin-Off[107]. Future Outlook and Risks - The Company faces risks typical of early-stage biotechnology firms, including the need for significant additional capital for research and development efforts[21]. - The Company’s future viability depends on its ability to raise additional capital to finance operations[33]. - The Company has incurred recurring losses since its inception and anticipates ongoing operating losses for the foreseeable future[31]. - The company anticipates needing to raise additional capital until it becomes profitable[191]. Clinical Trials and Product Development - The Company is focused on developing therapies for neurological and neuropsychiatric diseases, including epilepsy and mood disorders, with a broad pipeline of drug candidates[16]. - BHV-7000, the lead asset from the Kv7 platform, is currently in Phase 1 clinical trials, with expected results by the first half of 2023[132]. - The company aims to initiate at least one pivotal trial for BHV-7000 in epilepsy patients in the second half of 2023 if the Phase 1 study is successful[135]. - Taldefgrobep alfa (BHV-2000) is a Phase 3-ready anti-myostatin adnectin licensed from BMS, targeting neuromuscular diseases[144]. - The company commenced enrollment in a Phase 3 clinical trial of BHV-2000 for Spinal Muscular Atrophy, expecting to enroll approximately 180 patients[145].

Financial Data and Key Metrics Changes - For Q4 2021, NURTEC ODT achieved net sales of $190 million, a 40% increase from Q3 and a 440% increase year-over-year, driven by increased sales volume and improved managed care reimbursement [36][41] - Full year 2021 net sales for NURTEC ODT reached $462.5 million, growing $399 million or 627% compared to the previous year [41][42] - R&D investment for Q4 2021 on a non-GAAP basis was $76.4 million, a 32% increase from the prior quarter [39] - SG&A expense for Q4 2021 on a non-GAAP basis was $189.3 million, a 66% increase from the prior year quarter [40] Business Line Data and Key Metrics Changes - The oral CGRP market generated over $1 billion in revenues in 2021, with Biohaven's revenues growing over 600% [36][37] - NURTEC ODT has become the number one prescribed migraine treatment in its class, with over 1.6 million prescriptions since launch [8][7] Market Data and Key Metrics Changes - The oral CGRP class recorded net sales of approximately $1 billion in 2021, representing a small fraction of about 5% to 6% of overall migraine prescriptions [16] - The oral CGRP class is expected to continue growing, with significant penetration into the generic triptan market [50][51] Company Strategy and Development Direction - The company is focused on expanding its global commercialization partnership with Pfizer for rimegepant, aiming to deliver dual therapy NURTEC ODT to a global market of approximately 1 billion migraine patients [19][20] - Biohaven is committed to advancing its pipeline with new acquisitions, including a Kv7 Ion Channel Activator for epilepsy and a myostatin targeting asset for spinal muscular atrophy [13][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of NURTEC ODT and the oral CGRP class, highlighting the need for innovative treatments in a highly dissatisfied market [50][51] - The company anticipates continued strong growth in 2022, despite typical seasonal factors affecting Q1 performance [53] Other Important Information - Biohaven announced the acquisition of Channel Biosciences, adding a Kv7 program for epilepsy to its pipeline, and licensed Taldefgrobep from Bristol-Myers Squibb for spinal muscular atrophy [27][90] - The company has access to approximately $1 billion of liquidity following its collaboration with Pfizer [44] Q&A Session Summary Question: Can you provide a sense of comfort around the Street's NURTEC-specific revenues for this year around $850 million? - Management did not provide specific guidance on revenue but indicated that they expect modest increases in expenses due to new promising assets [100][101] Question: Can you provide more color on the earlier returns to growth in Q1? - Management noted that while Q1 typically sees slower uptake, there has been a positive return to growth trends earlier than expected in 2022 [107][108]

NEUROINNOVATION® We Demand More for Patients. 4th Quarter and Full Year 2021 Earnings February 25, 2022 Ellie, living with migraine NYSE:BHVN © 2022 Biohaven Pharmaceuticals. All rights reserved. Agenda | --- | |---------------------------------------------------------------------------------------------------------------| | | | Opening Remarks \| Caroline Dircks, Ph.D., Vice President Corporate Operations | | Company Achievements \| Vlad Coric, M.D., Chief Executive Officer | | 4Q and Year End 2021 Financi ...